2018-02-23 AiCuris’ Licensee MSD launches PREVYMIS™ (letermovir) in Germany
Pressemitteilungen zu Letermovir:
2018-01-31_AiCuris_PM_Letermovir_EU_Zulassung
2017-11-13 PR AiCuris_PM_Letermovir_CHMP EU
2017-11-09 PR AiCuris_PM_Letermovir_Approval
2016-10-19 PR AiCuris_Pressemitteilung_MSD_Letermovir_PH_3
2014-07-24 PR Merck News release 07 24 14 -Phase 3 Study of MK-8228
2013-05-08 PR Breakthrough Alliance Award
2012-10-15 PR AICURIS AND MERCK ENTER EXCLUSIVE WORLDWIDE
2012-02-14 PR AiCuris Medikament Letermovir AIC246 Wirksamkeits-Endpunkte in Phase 2
Vorstellung der Redner
o Dr. Holger Zimmermann
o Prof. Dr. Helga Rübsamen-Schaeff
o Dr. Dr. med Kristian Löbner
o Dr. Thomas Strüngmann